United Therapeutics

UTHR

Silver Spring, United States· Est. 1996

unither.com

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

UTHR · Stock Price

USD 569.18+267.76 (+88.83%)

Market Cap: $24.2B

Historical price data

Market Cap: $24.2BPipeline: 133 drugs (32 Phase 3)Founded: 1996Employees: 1,000-5,000HQ: Silver Spring, United States

Sector Ranking#85 in Small Molecule Drugs #17 in Drug Delivery & Formulation

Overview

Founded on a personal mission to treat pulmonary arterial hypertension, United Therapeutics has grown into a diversified, multi-platform biotech leader with a $26B+ market cap. The company successfully commercializes a portfolio of PAH therapies while aggressively pursuing its 'Mozart' moonshot to create an unlimited supply of transplantable organs. This dual strategy balances near-term financial strength from its rare disease franchise with transformative, long-term value creation in organ manufacturing and regenerative medicine.

Pulmonary Arterial HypertensionOrgan TransplantationRare Genetic Diseases

Technology Platform

A multi-modal platform integrating advanced prostacyclin delivery systems, genetic engineering for xenotransplantation (porcine organs), ex-vivo lung perfusion (EVLP), and regenerative medicine technologies to treat diseases and address the organ shortage.

Pipeline

133

133 drugs in pipeline32 in Phase 3

Drug	Indication	Stage
Remodulin	Pulmonary Arterial Hypertension	Approved
Remodulin (treprostinil sodium)	Pulmonary Arterial Hypertension	Approved
Treprostinil	Pulmonary Arterial Hypertension	Approved
Intravenous Treprostinil	Pulmonary Arterial Hypertension	Approved
Intravenous/Subcutaneous Treprostinil; Oral Treprostinil	Pulmonary Arterial Hypertension	Approved

Funding History

Total raised:$560M

Debt$500MUndisclosedAug 15, 2020

IPO$60MUndisclosedMay 27, 1999

FDA Approved Drugs

ACETAMINOPHEN AND IBUPROFENANDAFeb 28, 2023

TYVASO DPINDAMay 23, 2022

NAPROXEN SODIUM AND DIPHENHYDRAMINE HYDROCHLORIDEANDAMay 10, 2019

Opportunities

The company has a dual massive market opportunity: 1) Expanding its dominant franchise in the multi-billion-dollar pulmonary hypertension market through label expansions and next-gen oral therapies, and 2) Pioneering the potentially hundred-billion-dollar market for manufactured, transplantable organs, beginning with kidneys and lungs, to solve the chronic global organ shortage.

Risk Factors

Key risks include the unprecedented regulatory and clinical hurdles for xenotransplantation (long-term safety, zoonosis), heavy reliance on the PAH franchise which faces future patent expirations, and the execution risk of balancing massive, long-term 'moonshot' investments with sustaining near-term profitability and shareholder returns.

Competitive Landscape

In PAH, UTHR competes with large pharma (J&J, Bayer, Pfizer) on drug classes, but holds a unique moat with its proprietary prostacyclin delivery systems. In organ manufacturing, it is a leader in xenotransplantation (vs. eGenesis, academia), leveraging first-in-human success and integrated platforms (EVLP, genetics), though the field is nascent and competition is intensifying.